Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...
Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...
Novotech, a global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to ...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in its ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
11h
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...
Medicus Pharma provides update on SKNJCT-003 phase 2 study to treat nodular basal cell carcinoma: Philadelphia Monday, February 17, 2025, 18:00 Hrs [IST] Medicus Pharma Ltd., a bi ...
FibroGen, Inc. (NASDAQ:FGEN – Get Free Report) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback